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Abstract Two forms of glycine transporter have been described
to date, GlyT-1 and GlyT-2. The GlyT-2 form is expressed
mainly in the spinal cord, brainstem and cerebellum. Here we
describe the identification of a variant form of the human GlyT-2
(SC6), showing three amino acid changes to the previously
reported protein. Population analysis identified the allele causing
one of the polymorphisms, D463N, at 10% within the population
with 3% being homozygous for the change. We also transfected
our new variant into mammalian cells and compared it to the
published cDNA, showing that the three amino acid changes
present have no major effect on the biochemical properties of the
transporter.
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1. Introduction
The amino acid glycine is an important neurotransmitter in
the mammalian CNS. Two distinct glycinergic systems have
been described. Firstly, glycine acts as a major inhibitory neu-
rotransmitter in the spinal cord and brainstem. The inhibitory
e¡ects of glycine are mediated by strychnine-sensitive glycine
receptors, via gating of a Cl3 channel [1]. Secondly, glycine
modulates excitatory neurotransmission by acting via strych-
nine-insensitive regulatory sites on NMDA receptors to po-
tentiate the action of glutamate [2].
The actions of glycine are thought to be terminated by
rapid uptake via glycine transporters. These transporters are
members of the Na/Cl3-dependent family, which also in-
cludes transporters for GABA and monoamines [3]. The ¢rst
class of glycine transporter to be described (GlyT-1) was re-
ported to occur in at least three separate isoforms (GlyT-1a,
-1b, -1c) encoded by a single gene [4]. GlyT-1 is widely ex-
pressed in brain and spinal cord, and is present predominantly
on glial cells [5]. Tissue localisation studies suggest that GlyT-
1 may be co-localised with the glycine regulatory sites present
on NMDA receptors [6].
The second class of glycine transporters, GlyT-2, is encoded
by a unique gene and shares 48% amino acid sequence identity
with GlyT-1 [7,8]. GlyT-2 shows substantially di¡erent prop-
erties to those of GlyT-1. It is expressed mainly in spinal cord,
brainstem and cerebellum, and is present mostly on neuronal
cells [5]. Localisation studies indicate that the distribution of
GlyT-2 correlates with that of strychnine-sensitive glycine re-
ceptors [9]. GlyT-2 is also pharmacologically distinguishable
from GlyT-1 by its insensitivity to inhibition by sarcosine,
which is a substrate of GlyT-1 [8,10,11].
Many polymorphisms in the human GlyT-2 gene have been
identi¢ed [9,12,13]. However, it is not clear which of these
exist in the human population, or what their relative frequen-
cies are. In addition, the in£uence of the variations on the
functional activity of the resultant protein in terms of glycine
transport is not known. Here we describe the cloning, expres-
sion, functional analysis and frequency population assessment
of a novel GlyT-2 variant not reported previously.
2. Materials and methods
2.1. Cloning of human GlyT-2 SC6 variant
Human spinal cord Poly(A) RNA (Clontech) was used as a tem-
plate for the production of ¢rst strand cDNA template. This was
carried out using the Reverse Transcription System (Promega). The
reaction mixture contained ¢nal concentrations of 1URT bu¡er,
1 mM dNTPs, 5 mM MgCl2, 10 U RNasin ribonuclease inhibitor,
7.5 U AMV reverse transcriptase, 0.25 Wg Oligo (dT)15 primer, and
500 ng spinal cord Poly(A) RNA template. Reverse Transcription
was carried out at 42‡C for 60 min and followed by 5 min at 99‡C.
The ¢rst strand cDNA was then diluted 1 in 10 for subsequent PCR
reactions.
For full length PCR, human gene speci¢c primers were used as
follows: 5P primer (5P-GCC ACC ATG GAT TGC AGT GCT
CCC AAG GA-3P), and 3P primer (5P-GGA CTA GCA CTG AGT
GCC CAG TTC C-3P). Final concentrations of reagents in PCR were
1UKlentaq cDNA Polymerase mix (Clontech), 1UKlentaq PCR
bu¡er, 0.2 mM dNTPs, 0.5 WM each primer, and 5 Wl spinal cord
¢rst strand cDNA template. Thermal cycling was then carried out at
95‡C for 2 min, followed by 35 cycles of 95‡C for 30 s, 62‡C for 30 s
and 68‡C for 4 min and ended with 10 min at 68‡C.
PCR products were separated by agarose gel electrophoresis and
puri¢ed by a silica membrane based method (QIAquick Gel Extrac-
tion Kit, Qiagen). The products were then cloned into topoisomerase
activated pcDNA3.1 vector (Invitrogen), and transformed into TOP10
Escherichia coli cells (Invitrogen). Clones containing the plasmid with
the insert in the correct orientation were identi¢ed by PCR colony
screening. Plasmid DNA was then extracted from suspension cultures
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of the selected clones by alkaline lysis followed by a silica membrane
based method (QIAprep Spin Miniprep Kit, Qiagen).
2.2. Sequence analysis
All sequencing was carried out with vector or gene speci¢c primers
using an ABI automated sequencer. Data obtained were analysed
using DNASTAR software.
2.3. Site directed mutagenesis
The full length variant hGlyT-2 clone in pcDNA3.1 (Invitrogen)
designated SC6, was used as template for site directed mutagenesis
by PCR (QuikChange Site-Directed Mutagenesis Kit, Stratagene).
The PCR was carried out with three gene speci¢c primers covering
the three sites of variation, and corresponding antisense primers.
Thermal cycling was carried out at 95‡C for 30 s followed by 14 cycles
of 95‡C for 30 s, 55‡C for 1 min and 68‡C for 16 min. The PCR
reaction mix was then digested with the enzyme Dpn1 for 2 h and
transformed into E. coli XL1-Blue supercompetent cells. A number of
colonies were picked and grown in suspension cultures. DNA was
extracted by alkaline lysis followed by a silica membrane based meth-
od (QIAprep Spin Miniprep Kit, Qiagen). Appropriate clones were
chosen for expression.
2.4. PCR reactions and sequence analysis from pituitary gland cDNA
PCR was carried out from a pool of 59 pituitary gland cDNAs
(Clontech) to determine sites of variation. Gene speci¢c primers de-
signed to amplify the full length sequence in six overlapping sections
were used. Final PCR reactions included 1UPCR bu¡er, 0.2 mM
dNTPs, 0.5 WM each primer, 1.25 U Platinum Taq DNA polymerase
(Life Technologies), 1.5 mM MgCl2 and 2.5 Wl pituitary gland cDNA
template. Thermal cycling was carried out at 95‡C for 2 min, followed
by 40 cycles of 95‡C for 30 s, 58‡C for 30 s, 68‡C for 1 min, and
¢nished with 7 min at 68‡C. PCR products were puri¢ed by a silica
membrane based method (QIAquick PCR Puri¢cation Kit, Qiagen)
and sent for direct sequencing with gene speci¢c primers.
2.5. Transient transfection of HEK293 cells
HEK293 cells were cultured in MEM supplemented with 10% foetal
bovine serum and 1Unon-essential amino acids (all supplied by GIB-
CO-BRL). The expression construct pcDNA3.1-GlyT-2.SC6 and the
equivalent published sequence construct were transfected into
HEK293 cells by the Lipofectamine-Plus procedure following the
manufacturers protocol (GIBCO-BRL). After transfection, cells
were seeded onto poly-lysine coated 96-well plates (Becton Dickinson)
at 50 000 cells/well, and assayed for glycine transport.
Fig. 1. Multiple alignment of the amino acid sequence of the SC6 clone (GT2sc6), the wild-type GlyT-2 (GT2wt) and the GlyT-1 gene (GT1c).
The amino acid positions where variations were found are highlighted.
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2.6. Glycine uptake assays
Transiently transfected cells were washed with Krebs/HEPES bu¡er
containing (mM): NaCl 140, KCl 5.5, MgSO4 0.8, CaCl2 1.8, HEPES
10, pH 7.4 (NaOH). Cells were then incubated for 30 min at 37‡C in
the same bu¡er containing 0.5 WM [3H]-glycine (15.7 Ci/mmol; Amer-
sham) and 0^1000 WM unlabelled glycine. The incubation was termi-
nated by washing with ice-cold bu¡er. Cells were then dissolved in
0.5 M NaOH, and the amount of radioactivity taken up by the cells
was measured by liquid scintillation counting. The protein content of
selected wells was also assessed using the Biorad protein assay. The
rate of uptake at each glycine concentration was calculated in terms of
pmol glycine/mg protein/min. Graphs of rate of uptake against glycine
concentration were plotted, and Km and Vmax values were calculated
(GraFit; Erithacus Software). Results are presented as means
þ S.E.M. of three separate assays.
2.7. Genotyping
Allele speci¢c ampli¢cation primers for the D463N polymorphism
were used in conjunction with a common reverse oligo. Two PCRs
were conducted for each DNA sample (one for each allele speci¢c
oligonucleotide) using the following conditions: 94‡C for 40 s, 60‡C
for 30 s, 35 cycles in 20 Wl reactions containing 10 pmol of each
primer, 1 U TaqExpress (GenPak Ltd.), 50 mM Tris-HCl pH 9.1,
16 mM ammonium sulphate, 3.5 mM MgCl2, 150 Wg/ml bovine serum
albumin, plus 25^100 ng of DNA. For each DNA, the two ASA
reactions [14] were run independently on 3% agarose gels and each
lane scored for presence and absence of each allele. Allele speci¢c
oligos used were: GlyT-2-2FG (D) 5P-ccaagtgggagaaactgacgg, Gly-
T-2-2FA (N) 5P-ccaagtgggagaaactgacga. Common reverse oligo:
GlyT-2-2R 5P-gtaccaagatcatcaggctc.
2.8. DNA samples
Blood was collected from USA residents and anonymised for name
and ethnic origin. DNA was extracted from leukocytes using the
Scotlab (Glasgow, UK) Nucleon kit.
3. Results and discussion
The full length human GlyT-2 [8,9,12] was obtained by
PCR from spinal cord cDNA template. This cDNA template
had been prepared from a pool of Poly(A) RNAs (11 indi-
viduals). The PCR reaction produced a band of the expected
2.4 kb size for the full length GlyT-2 gene, this band was
subcloned directly into the expression vector pcDNA3.1. Se-
Fig. 1 (continued).
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quencing analysis carried out on a number of full length
clones revealed several single nucleotide di¡erences compared
to the ‘consensus’ sequence reported by Albert et al. [12]. One
clone, described here as SC6, showed four nucleotide di¡er-
ences which resulted in three amino acid di¡erences at posi-
tions 184, 463 and 751 of the translated protein (see Fig. 1
and Table 1).
We proposed at this stage that the changes identi¢ed de-
rived from di¡erences between individuals that represented
the pooled samples in the starting RNA template. Interest-
ingly, the amino acid di¡erence at position 463 from an as-
partic acid residue (D) to an asparagine (N) (see Fig. 1 and
Table 1) was reported among a number of variations in this
gene [12]. In light of this, we proceeded to validate the pres-
ence and frequency of the three amino acid variations in our
SC6 clone in a larger number of individuals, along with eval-
uating functional and pharmacological characteristics in vitro.
Initially, PCR was carried out from a pool of 59 human
pituitary gland cDNAs. Sequencing results from PCR prod-
ucts obtained con¢rmed one of the di¡erences initially identi-
¢ed in the SC6 clone. This was the change at nucleotide posi-
tion 1387 in the coding region, D463N. Other potential
polymorphisms were also identi¢ed (results not shown).
A detailed genotyping analysis was performed, to assess the
population frequency of this con¢rmed variation. This analy-
sis was carried out on a random selection of 312 US citizens.
Results obtained from this analysis con¢rmed the existence of
this variation in the population. The gel in Fig. 2 illustrates
the identi¢cation of individuals containing the GATCAAT
(D463N) variation. We discovered that the allele containing
the AAT codon is present at a frequency of approximately
10% within the population, with 3% of this sample being
homozygous for this change. Genotyping results are summar-
ised in Table 2.
Another of the SC6 variations, the change at position 751
from a valine residue (V) to an alanine (A), was con¢rmed in
PCR reactions from a number of di¡erent genomic templates.
This again con¢rmed a real polymorphism of the gene. A
Table 1
Description of nucleotide and amino acid changes identi¢ed in
hGlyT-2 variant SC6
Di¡erence Nucleotide change in SC6 Amino acid change
1 129 gcTCgcC 43 (none) ACA
2 551 cAaCcGa 184 QCR
3 1387 GatCAat 463 DCN
4 2252 gTgCgCg 751 VCA
This clone was obtained from a pool of 11 spinal cord Poly(A)
RNAs. The A of the ATG is taken as position number 1 in the nu-
cleotide sequence.
Fig. 1 (continued).
Table 2
Genotype totals and calculated allele frequencies for the GlyT-2
D463N polymorphism in 312 US citizens
Genotype DD DN NN
N 260 42 10 total = 312
allele frequencies D = 90%, N = 10%
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detailed population analysis was not performed in this case.
We were unable to con¢rm in the large number of templates
the third di¡erence found in our SC6 clone (at position 184 of
the translated protein).
In order to test the e¡ects of the three variations found in
the SC6 on the functionality of the protein we transiently
transfected HEK293 cells and assessed glycine uptake. Fig.
3 shows the results obtained from HEK293 cells transiently
transfected with either SC6 or the previously reported clone,
evaluated in a [3H]-glycine uptake assay. Results showed that
the two transfects had similar Km values for glycine uptake
(162 þ 33 WM for SC6; 160 þ 45 WM for wild-type), though
Vmax values were somewhat higher for the wild-type sequence
(3734 þ 533 pmol/mg protein/min) than for SC6 (1648 þ 414
pmol/mg protein/min). This could be due to di¡erences in
protein expression levels between the two transfects. Overall,
the functional characteristics of the variant were not di¡erent
from the published form of the gene, suggesting that the three
amino acid changes reported have no major e¡ect on func-
tional activity of hGlyT-2.
Many individual variations have been reported in the hu-
man GlyT-2 gene [12] although no work has described
whether there are signi¢cant pharmacological di¡erences as-
sociated with any of them. In this report we have identi¢ed
the presence of a variant form (SC6) of this gene and showed
that two of the amino acid changes reported are present in
our test population. We reported the presence of a variation
in amino acid 463 DCN of the GlyT-2 gene. We also con-
¢rmed the presence in the population of a change from VCA
at position 751 of the protein and the presence in our pop-
ulation of further variations.
We have seen no major di¡erences in glycine transport be-
tween the published GlyT-2 sequence and our variant. Further
genotyping work would be required to look in detail at the
polymorphisms within the population for this gene. It would
be relevant to assess the frequencies of combinations of all the
di¡erent polymorphisms reported for the GlyT-2 gene, and to
test their functionalities.
The array of polymorphisms found within the GlyT-2 gene
provides a useful tool for future pharmacogenetic and disease
association studies, which may help target relevant diseases
for GlyT-2 based agonists and antagonists.
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